Free Trial
NASDAQ:TGTX

TG Therapeutics (TGTX) Stock Price, News & Analysis

TG Therapeutics logo
$37.73 -0.19 (-0.51%)
As of 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About TG Therapeutics Stock (NASDAQ:TGTX)

Key Stats

Today's Range
$37.38
$38.39
50-Day Range
$33.37
$45.37
52-Week Range
$16.65
$46.48
Volume
895,601 shs
Average Volume
2.89 million shs
Market Capitalization
$5.99 billion
P/E Ratio
157.13
Dividend Yield
N/A
Price Target
$43.80
Consensus Rating
Moderate Buy

Company Overview

TG Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

TGTX MarketRank™: 

TG Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 201st out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TG Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    TG Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about TG Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for TG Therapeutics are expected to grow by 1,150.00% in the coming year, from $0.08 to $1.00 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TG Therapeutics is 157.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.65.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TG Therapeutics is 157.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.52.

  • Price to Book Value per Share Ratio

    TG Therapeutics has a P/B Ratio of 26.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about TG Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    16.71% of the float of TG Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    TG Therapeutics has a short interest ratio ("days to cover") of 9.5.
  • Change versus previous month

    Short interest in TG Therapeutics has recently increased by 0.51%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    TG Therapeutics does not currently pay a dividend.

  • Dividend Growth

    TG Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.71% of the float of TG Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    TG Therapeutics has a short interest ratio ("days to cover") of 9.5.
  • Change versus previous month

    Short interest in TG Therapeutics has recently increased by 0.51%, indicating that investor sentiment is decreasing.
  • News Sentiment

    TG Therapeutics has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for TG Therapeutics this week, compared to 8 articles on an average week.
  • Search Interest

    Only 5 people have searched for TGTX on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TG Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $369,400.00 in company stock.

  • Percentage Held by Insiders

    10.64% of the stock of TG Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    58.58% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about TG Therapeutics' insider trading history.
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
TG Therapeutics, Inc. (TGTX) - Yahoo Finance
TGTX - TG Therapeutics Inc Financials - Morningstar
See More Headlines

TGTX Stock Analysis - Frequently Asked Questions

TG Therapeutics' stock was trading at $30.10 at the beginning of 2025. Since then, TGTX shares have increased by 25.6% and is now trading at $37.8150.

TG Therapeutics, Inc. (NASDAQ:TGTX) posted its quarterly earnings data on Wednesday, May, 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by $0.16. TG Therapeutics's quarterly revenue was up 90.4% compared to the same quarter last year.
Read the conference call transcript
.

TG Therapeutics' top institutional shareholders include NorthCrest Asset Manangement LLC (0.01%). Insiders that own company stock include Michael S Weiss, Sean A Power, Yann Echelard, Laurence N Charney and Sagar Lonial.
View institutional ownership trends
.

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TG Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
5/07/2025
Today
7/10/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TGTX
CIK
1001316
Employees
290
Year Founded
N/A

Price Target and Rating

High Price Target
$55.00
Low Price Target
$22.00
Potential Upside/Downside
+8.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
156.83
Forward P/E Ratio
470.69
P/E Growth
N/A
Net Income
$23.38 million
Pretax Margin
10.80%

Debt

Sales & Book Value

Annual Sales
$329 million
Cash Flow
$0.13 per share
Price / Cash Flow
296.84
Book Value
$1.43 per share
Price / Book
26.33

Miscellaneous

Free Float
141,863,000
Market Cap
$5.98 billion
Optionable
Optionable
Beta
1.91

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:TGTX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners